-
2024-514228-18-00
4
2025-01-16
Asthma in adults who remain uncontrolled despite medium to high dose I
-
2023-504359-29-01
5
2024-12-11
Multiple sclerosis
-
2024-514343-29-00
5
2024-11-19
multiple sclerosis
-
2023-509237-39-00
5
2022-08-02
Myelin oligodendrocyte glycoprotein antibody-associated disease (MOG-A
-
2023-505974-14-00
5
2022-06-23
Multiple Sclerosis (MS)
-
2023-509372-41-00
5
2022-01-30
Multiple Sclerosis
-
2024-513527-17-00
4
2021-06-07
Multiple Sclerosis
-
2023-507906-15-00
5
2019-01-30
Relapsing multiple sclerosis (RMS)
-
2023-507889-89-00
5
2016-02-19
Respiratory tract infection
-
2022-502049-91-00
4
2023-09-26
SEVERE COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA (SCABP)
-
2023-507410-27-00
4
2024-06-19
Severe Asthma
-
2023-503693-20-01
5
2024-04-10
Severe eosinophilic asthma
-
2023-506197-12-00
4
2024-02-07
Dyslipidemia
Dyslipidemias are alterations to the plasma lipid profile
-
2023-503333-22-00
5
2024-01-15
Moderate to severe controlled asthma according to Step 4 and Step 5 of
-
2022-502854-16-00
4
2023-11-26
Asthma
-
2022-502208-64-00
4
2023-11-25
Asthma
-
2022-502552-31-00
4
2023-10-03
Relapsing Forms of Multiple Sclerosis
-
2022-502234-70-00
5
2023-07-14
Chronic Obstructive Pulmonary Disease (COPD)
-
2022-503022-13-00
5
2023-06-08
Hypertriglyceridemia, Cardiovascular Diseases, Atherosclerosis
-
2023-510172-31-00
5
2022-04-22
Chronic obstructive pulmonary disease (COPD)
-
2023-505975-54-00
5
2022-03-28
Multiple Sclerosis (MS)
-
2023-505203-23-01
5
2021-07-26
Severe asthma with an eosinophilic phenotype
-
2023-505786-88-00
5
2021-04-25
Severe and inadequately controlled asthma
-
2024-514495-41-00
5
2020-11-04
Primary Progressive Multiple Sclerosis